Vistagen Therapeutics, Inc. (VTGN) stock
VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.19+0.00 (+2.01%)
Close on Nov 17, 2026Market cap $8.34MP/E –Yield –
Vistagen Therapeutics price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Vistagen Therapeutics's price to book ratio was 0.3× on Nov 11, 2026, against 2.4× a year earlier. Over the last 5 years it ranged from 0.2× to 5.5×, with a median of 0.9×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 0.3× | −0.0 |
| 2025 | Dec 31, 2025 | 0.3× | −0.6 |
| 2024 | Dec 31, 2024 | 1.0× | −0.2 |
| 2023 | Dec 29, 2023 | 1.1× | +0.4 |
| 2022 | Dec 30, 2022 | 0.7× | −3.0 |
| 2021 | Dec 31, 2021 | 3.7× | −20.3 |
| 2020 | Dec 31, 2020 | 24.0× | +0.6 |
| 2019 | Oct 31, 2019 | 23.3× | +15.3 |
| 2018 | Dec 31, 2018 | 8.0× | −17.0 |
| 2017 | Jul 31, 2017 | 25.1× | +23.5 |
| 2016 | Dec 30, 2016 | 1.6× | – |
See a number that looks wrong?